Fig 1: SARS-CoV-2 spike-specific humoral response following BNT162b2 mRNA vaccination in naive subjects and individuals recovered from COVID-19(A) Experimental design. Blood samples were collected 5 days before BNT162b2 mRNA vaccination (sample 0), 14 days after the first dose (sample 1), and 14 days (sample 2) and 230 days (sample 3) after the second dose.(B) Concentrations of plasma anti-spike S1 IgA (left panel) and anti-receptor binding domain (RBD) IgA (right panel) antibodies.(C) Concentrations of plasma anti-spike S1 IgG (left panel), anti-RBD IgG (central panel), and anti-full spike IgG (right panel) antibodies.(D) Concentration of neutralizing antibodies in plasma by means of a competitive assay; 108/free anti-spike signal is depicted.(E) Heatmap of Z score of IgA, IgG, and anti-spike neutralizing antibodies.(F) Uniform manifold approximation and projection (UMAP) of peripheral blood mononuclear cells (PBMCs) followed by manual gating to identify the indicated populations.(G) UMAP of B cells followed by manual gating to identify the indicated populations in sample 2.(H) UMAP clustering expressions of HLA-DR, IgD, IgM, and IgG on B cells.(I) Frequency of SARS-CoV-2 spike-specific B cells in gated CD19+ cells in sample 3.(B, C, D, and I) Data shown as mean ± SEM (ns, not significant; *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001). Unpaired Student's t test in samples 0, 1, 2, or 3. (B, C, and D) Two-way ANOVA analyzing the time course (denoted by vertical bar, |). n = 16 naive, n = 11 recovered from COVID-19.See also Figures S1, S2, and S3A.